Free · no account · quoted from the filing

What changed in PFE's 10-Q

Source: 10-Q filed 2026-05-05 · compared against 10-Q 2025-11-04. Every passage below is quoted verbatim from the filing itself.

Segments

This filing

Beginning in the first quarter of 2026, we manage our commercial operations through a global structure consisting of two operating segments: Biopharma and PC1.

Business Development

This filing

our acquisition of Metsera in November 2025

Revenue

This filing

Total revenues increased $736 million, or 5%

Intellectual Property

This filing

We anticipate a significant reduction of revenue from patent-based or regulatory exclusivity expiries in 2026 through 2030

Regulatory

This filing

the U.S. Government announced Section 232 tariffs on imported patented pharmaceuticals and their ingredients, up to a 100% duty

Tax

This filing

the OBBBA was enacted into law in the U.S. ... permanent extension of certain expiring provisions

Pipeline

This filing

Veppanu ... approved ... May 2026 (U.S.)

What it means — the analyst reading

The passages above are the company's own words. The plain-English reading of them — what changed, why it matters, and the direction of travel — is part of the Filing Change Monitor.

See the Filing Change Monitor →

Compared from narrative excerpts (outlook, risks, MD&A) of both filings — quotes are verbatim from the new filing. Not advice. Source: company SEC filings via stockportfolio.pro. Educational, not investment advice.